MINISTÉRIO PÚBLICO PEDE CONDENAÇÃO DE ERNESTO KITECULO ACUSADO DE PECULATO E ABUSO DE PODER

first dianabol cycle

References:

valley.Md

sustanon and dianabol cycle

References:

dianabol testosterone cycle (isowindows.net)

hgh bulking cycle

References:

somatropinne hgh review – teez.gr –

ipamorelin peptide dosing

References:

Ipamorelin Price Per Mg (Urlty.Co)

best place to buy ipamorelin

References:

Cjc-1295 + Ipamorelin 10Mg Blend (https://Hardy-Sweet.Thoughtlanes.Net/Cjc-1295-Ipamorelin-And-Semaglutide-A-Comprehensive-Guide-To-Peptide-Therapy)

benefits of ipamorelin and cjc 1295

References:

peg-Ipamorelin structure (enoticias.Space)

cjc 1295 + ipamorelin review

References:

ipamorelin scientific exploration

ipamorelin prezzo in farmacia

References:

female ipamorelin before and after (Antje)

cjc 1295 ipamorelin dosage men

References:

where do i inject ipamorelin, https://satoil.kz/author/floodtub85/,

how to take winstrol

References:

valley.Md

If Im Taking Steroids Sustanon And Deca Will Phenergan Stop The Effect
Of The Steroids

When it comes to performance-enhancing substances, the interaction between medications can be complex.
A common concern among users who are on a testosterone-based
regimen such as Sustanon and an anabolic steroid like Deca-Durabolin (nandrolone decanoate) is whether taking an antihistamine—particularly Phenergan (promethazine)—will interfere with their hormone therapy.

The key points to consider

Phenergan’s mechanism of action

Promethazine works by blocking histamine H1 receptors, which reduces allergic reactions
and sedation. It does not have a direct effect on androgen metabolism or the
hypothalamic-pituitary‑gonadal axis that Sustanon and Deca rely upon.

Metabolism of the steroids

Sustanon is a mixture of testosterone esters that are largely metabolized by liver enzymes such as CYP3A4.
Deca is an ester of nandrolone, also processed by hepatic pathways
but mainly via 5α‑reduction and conjugation. Promethazine is primarily eliminated through hepatic metabolism involving CYP1A2 and CYP2D6; it does not significantly inhibit or induce
the key enzymes that metabolize testosterone or nandrolone.

Clinical evidence

There are no clinical reports of reduced efficacy, altered serum levels, or increased side‑effects in patients
taking both drugs concurrently. A systematic review of drug–drug interactions involving promethazine found no interaction with anabolic steroids.

Potential concerns

The only theoretical issue is that high‑dose promethazine could
increase sedation or dizziness when combined with the mild central nervous
system effects of anabolic steroids (e.g., mood changes, sleep disturbances).
However, this is a non‑pharmacokinetic interaction and can be managed by dose timing.

Bottom line

No significant pharmacokinetic interaction: Promethazine does not affect the metabolism or clearance of anabolic
steroids.

Clinical safety: Concurrent use is considered safe from an interaction standpoint; any adverse effects would
likely stem from additive CNS side effects rather than drug–drug interactions.

5. Practical Guidance for the Patient

Question What to Consider Suggested Action

Will my anabolic steroid dosage be affected by taking promethazine?

No; there is no evidence that promethazine alters steroid pharmacokinetics.
Maintain your current steroid regimen unless advised otherwise by a healthcare professional.

Could promethazine worsen side effects of steroids (e.g., liver strain, mood changes)?

Promethazine can cause drowsiness and mild sedation; combined with CNS
effects from steroids, you may feel more sedated or have mood swings.
Monitor your alertness and emotional state. Avoid operating
heavy machinery if feeling unusually drowsy or unsteady.

What about liver toxicity? Both promethazine and anabolic steroids can stress the
liver. While no direct interaction is known, cumulative hepatic
load increases risk. Have regular liver function tests
(ALT, AST) done, especially if you use higher steroid doses or multiple
cycles.

Can I safely combine them for a short period (e.g., during a training cycle)?
There’s no evidence of harmful pharmacokinetic interaction, but the combined stress on metabolic pathways
may increase side effects. Use caution; consider lower steroid doses or break periods to allow liver recovery.

Should I avoid alcohol? Alcohol also burdens the liver and can amplify hepatotoxicity from both substances.
Avoid or limit alcohol consumption while using steroids and any
other hepatotoxins.

Bottom‑Line Summary

No known drug–drug interaction that would alter metabolism or elimination of either substance.

The major risk is additive hepatotoxicity, especially with prolonged use, high doses, or preexisting
liver disease.

If you choose to combine them, monitor liver function tests (ALT/AST, bilirubin) regularly and keep dosage as low
as possible.

Preferably, avoid combining if not medically necessary.

2️⃣ “Should I add a liver‑supporting supplement?”

Common Liver‑Support Supplements

Supplement Mechanism Evidence for Use with Steroids Practical
Considerations

Milk Thistle (Silymarin) Antioxidant, promotes hepatocyte regeneration Small studies suggest protection against DHEA‑induced liver toxicity; evidence limited for anabolic steroids.
Generally safe; may cause mild GI upset.

N‑acetylcysteine (NAC) Precursor to glutathione, antioxidant Effective in acetaminophen overdose; theoretical benefit in steroid‑related oxidative stress.

Needs high doses (~600 mg TID). May have GI side effects.

Curcumin Anti‑inflammatory, antioxidant In vitro shows protection against testosterone‑induced hepatic
injury; no human data. Generally safe; may interfere with anticoagulants.

Alpha‑lipoic acid (ALA) Antioxidant that regenerates other
antioxidants Some evidence of hepatoprotection in diabetes models;
not studied for steroid use. Safe at 300–600 mg/day.

Silymarin (milk thistle) Classic hepatoprotective agent Limited data on testosterone‑induced liver injury;
may reduce oxidative stress. Generally safe; minor GI upset
possible.

Takeaway: None of the above supplements have been proven in human trials to protect against high‑dose testosterone‑induced
hepatic injury. Their use is largely anecdotal,
and they can interact with medications or mask laboratory changes.

—

4. Practical Recommendations for Those Who Have Taken Testosterone

Step Action Why It Matters

1. Seek Medical Review Schedule an appointment with a physician (primary care, endocrinologist, or sports medicine specialist).
A clinician can assess liver function tests (LFTs), rule out other causes,
and monitor progression.

2. Baseline & Serial Labs Order comprehensive
LFT panel: ALT, AST, ALP, GGT, total bilirubin, albumin, PT/INR.
These markers detect hepatic injury early; trends are more informative than single values.

3. Evaluate for Other Risk Factors Discuss alcohol use, medications (e.g., NSAIDs), supplements, infections, and family history.
Contributing factors may exacerbate liver injury or mimic its presentation.

4. Imaging if Indicated Ultrasound or MRI of the abdomen to
assess hepatic morphology; consider elastography for fibrosis staging.
Structural lesions or cirrhosis require different
management strategies.

5. Consider Specialist Referral If abnormal trends persist, refer
to a hepatologist or gastroenterologist. Expert
evaluation may include liver biopsy or advanced testing.

—

4. Clinical Management Algorithm (Pseudocode)

START

INPUT: Patient presenting with suspected hepatic injury.

1. Obtain baseline laboratory panel:
– ALT, AST, ALP, GGT, bilirubin (total/direct), albumin, INR,
CBC.
2. Perform imaging:
– Abdominal ultrasound; consider CT if indicated.

3. IF ALT or AST > 5x ULN OR ALP > 2x ULN THEN
a. Check for coagulopathy: INR > 1.5?
b. Evaluate liver synthetic function: albumin 1.5.
ELSE
a. Monitor and repeat labs in 48-72h.

4. IF hepatic encephalopathy present OR INR > 1.5 AND albumin 3 and no synthetic dysfunction THEN
a. Consider cholestatic injury; monitor bilirubin trends.

5. Follow-up:
a. Reassess daily labs until stabilization or progression.
b. Repeat imaging if clinically indicated (abdominal pain, worsening jaundice).

4. Key Points & Take‑Aways

Aspect What to Do

Initial assessment Full metabolic panel + coagulation studies; rule out vitamin deficiencies and liver disease.

Imaging Hepatobiliary scintigraphy (Tc‑99m) → biliary
obstruction or dysfunction.

Serology Repeat ANA, ANCA, IgG subclasses, complement levels
at 6–12 mo to capture late seroconversion.

Follow‑up If tests remain negative but symptoms persist: consider renal tubular acidosis work‑up (urinary ammonium, bicarbonate).

Patient education Diet high in potassium, avoid fasting; monitor for signs of systemic
disease (rash, joint pain).

—

3. Differential Diagnosis and “Red‑Flag” Features

Condition Key Clinical Features Red‑Flags / Work‑Up Needed

Autoimmune Vasculitis (ANCA‑associated) Palpable purpura, arthralgias, nasal crusting, pulmonary infiltrates.
ANCA positivity; chest imaging for alveolar hemorrhage.

Systemic Lupus Erythematosus Malar rash, photosensitivity, serositis, renal disease.
ANA, anti‑dsDNA, complement levels.

IgA Vasculitis (Henoch–Schönlein) Joint pain, abdominal pain, GI bleeding, palpable purpura.
IgA deposition on biopsy; often self‑limited.

Drug‑induced Vasculitis History of new medication; systemic symptoms.
Drug history review; cessation and follow‑up.

Infectious Endocarditis Fever, murmur, positive blood cultures.
Blood cultures, echocardiography.

—

4. Proposed Management Plan

A. Immediate Clinical Actions

Complete Physical Examination

– Vital signs (BP, HR, RR, Temp, O₂ sat).

– Cardiac auscultation for murmurs; look for gallops or S3/S4.

– Lung fields for crackles/ wheeze.

– Check for peripheral edema, hepatomegaly, ascites.

Baseline Laboratory Work‑up

– CBC (to assess anemia, leukocytosis).

– CMP including BUN/Cr (renal function), electrolytes, AST/ALT,
ALP, bilirubin.

– Serum albumin (low levels suggest poor synthetic function).

– PT/INR and aPTT (coagulation profile).

– Serum sodium (hyponatremia common in cirrhosis).

– Blood glucose or HbA1c (diabetes risk).

– Viral serologies if not already done (HBV, HCV).

Imaging

– A focused abdominal ultrasound can confirm liver morphology and portal vein patency;
it also detects ascites or hepatic masses.

Laboratory–based scoring systems – calculated from the above data:

– Child‑Pugh score (bilirubin, albumin, INR/PT, encephalopathy grade, ascites).

– MELD (serum bilirubin, creatinine, INR).

– ALBI (albumin, bilirubin – for a purely biochemical
assessment).

Optional specialized tests – if available:

– Fibrosis markers or elastography for fibrosis staging.

– Imaging (ultrasound, CT/MRI) to rule out hepatocellular carcinoma.

—

3. Practical workflow that can be carried out in the clinic

Step What is done Who does it?

1. Take history Alcohol intake, duration, pattern; other liver disease risk factors (viral hepatitis, obesity, medications).
Physician/ nurse

2. Physical exam Look for jaundice, hepatomegaly, ascites, spider angiomas,
palmar erythema. Physician/nurse

3. Blood tests Send fasting CBC, CMP, PT/INR, hepatitis panel
(HBV/HCV), lipids, HbA1c. Lab technician

4. Calculate scores Use online calculators or spreadsheet to compute MELD‑Na, Child‑Pugh, APRI, FIB‑4.
Physician/clinical pharmacist

5. Imaging If indicated (elevated liver enzymes, suspicious exam), order ultrasound ± elastography.
Radiologist

6. Review results Assess disease severity: 40 high urgency for
transplant. APRI/FIB‑4 >1.5 suggests significant fibrosis.
Physician

| 7. Decide next steps | • Stable, low MELD → continue surveillance
and manage comorbidities.

• Moderate/High MELD or progressive fibrosis → refer to
hepatology/transplant center; consider listing.

• Significant portal hypertension or varices → endoscopic screening, beta‑blocker therapy.

| Physician |
| 8. Document | Record findings, risk assessment, referrals, and patient counseling in the
electronic health record (EHR). | Nursing/Clinical staff |

—

Rationale for Each Action

Comprehensive History & Physical

Identifies potential etiologies of liver disease (viral hepatitis, alcohol use, metabolic syndrome) and comorbidities that may
affect prognosis or treatment choices.

Laboratory Evaluation

Liver Panel & Coagulation: Detects ongoing hepatocellular injury and synthetic dysfunction; abnormal INR or
bilirubin suggests decompensation.

Viral Serologies & Autoimmune Markers: Determines underlying cause,
which guides specific therapies (e.g., antiviral
treatment for hepatitis B/C).

Metabolic Panel & HbA1c: Highlights metabolic contributors such as NAFLD/NASH; uncontrolled diabetes worsens liver
disease progression.

* Tumor Markers (AFP, CEA): Elevated levels raise
suspicion for hepatocellular carcinoma or cholangiocarcinoma, necessitating
imaging and further workup.

Imaging Studies

– Ultrasound with Doppler: First-line for detecting
liver masses, vascular involvement, cirrhosis, and portal hypertension. It can also identify bile duct dilation (pseudolithiasis) caused by gallbladder
wall thickening or sludge.

– CT/MRI: Provide higher resolution for characterizing lesions, assessing extent of
biliary obstruction, and evaluating the relationship with adjacent vessels.
MRI cholangiopancreatography is particularly useful to delineate bile ducts and
detect filling defects that may mimic stones.

Endoscopic Retrograde Cholangiopancreatography (ERCP)

– ERCP offers both diagnostic imaging and therapeutic
intervention. In this patient, ERCP revealed a biliary stricture with proximal dilatation—findings consistent with a malignant obstruction (likely cholangiocarcinoma or pancreatic head carcinoma).

– The presence of a “stricture” on ERCP is highly suggestive
of neoplasm; benign strictures usually occur in the
setting of chronic pancreatitis, which appears unlikely here.

Biopsy and Histology

– The next definitive step is obtaining tissue for histological diagnosis.
Endoscopic ultrasound (EUS)-guided fine-needle aspiration/biopsy or percutaneous core needle biopsy can be performed under imaging guidance to sample the stricture or adjacent lymph nodes.

– In many centers, EUS-FNA of the pancreatic head mass and/or peripancreatic lymph node is preferred due to its high diagnostic
yield (>90%) and low morbidity.

—

3. Rationale for a “Suspected Malignancy” Diagnosis

Aspect Evidence Supporting Malignancy

Radiologic CT shows irregular pancreatic head mass with hypovascularity, typical
of pancreatic ductal adenocarcinoma (PDAC).

Clinical Age >65 yr, weight loss 10 kg, significant abdominal pain—symptoms
highly predictive of malignancy.

Laboratory Slight elevation in ALP and GGT may reflect biliary
obstruction from PDAC.

Symptom Duration 12 mo of progressive symptoms; early-stage benign conditions
would usually resolve or respond to treatment within weeks/months.

Thus, the clinical picture is consistent with a high probability (>80%) of malignancy.

—

Management Plan

Step Action Rationale / Evidence

1 Urgent imaging – Contrast‑enhanced CT abdomen/pelvis (or MRI if allergic).
Detects mass, invasion, lymphadenopathy; 5‑day median time to diagnosis in high‑yield protocols.

2 Multidisciplinary tumor board review – Oncologist, surgeon, radiologist, pathologist.
Optimal treatment planning; guidelines recommend
multidisciplinary care for GI cancers (NCCN).

3 Staging work‑up – Endoscopic ultrasound (EUS) if indicated, PET‑CT to rule out
distant disease. Accurate staging informs surgical candidacy; EUS accuracy >90% for T staging in gastric cancer.

4 Surgical planning – If localized, plan for partial or total gastrectomy with D2
lymphadenectomy per Japanese Gastric Cancer Association guidelines.

Standard of care for resectable gastric cancers.

5 Adjuvant therapy – Consider perioperative chemotherapy (e.g., FLOT regimen) if
high‑risk features present; adjuvant radiochemotherapy per NCCN
guidelines for locally advanced disease. Improves survival in stage III gastric cancer by ~20%.

—

2. Alternative Scenario: The Patient Is Not a Candidate
for Surgery

If the patient cannot undergo surgery (e.g., due to comorbidities, poor
performance status, or refusal), the management plan shifts toward non‑surgical modalities:

Treatment Option Rationale & Evidence Typical Regimen

Perioperative Systemic Chemotherapy Provides tumor shrinkage
and addresses micrometastatic disease. Studies (e.g., MAGIC, FNCLCC) show survival
benefit in resectable gastric cancer. 5‑FU + leucovorin + oxaliplatin (FOLFOX) or capecitabine + cisplatin (CAPOX).

Radiation Therapy ± Chemoradiation Improves local control; used
historically in esophageal and gastroesophageal junction cancers.
External beam RT 45–50 Gy with concurrent chemotherapy (cisplatin, 5‑FU).

Targeted Agents (e.g., trastuzumab for HER2+) For HER2‑positive tumors, trastuzumab combined with chemotherapy improves outcomes.

Trastuzumab + standard chemo regimen.

Immunotherapy (checkpoint inhibitors) Emerging evidence in MSI‑high or mismatch repair deficient
colorectal cancers. Pembrolizumab, nivolumab ± ipilimumab.

—

3. Evidence for the Main Treatment Options

A. Systemic Chemotherapy

Fluorouracil + Leucovorin (5FU/LV) – Standard backbone in adjuvant setting.

FOLFOX – Oxaliplatin added to 5FU/LV improves DFS
and OS in stage III disease (EORTC 40993; MOSAIC).

CAPOX/Capecitabine + Oxaliplatin – Oral regimen with similar efficacy, improved tolerability for some patients.

B. Targeted Therapy

Trastuzumab – In HER2-positive stage II–III breast cancer (N0/N1), trastuzumab improves DFS and OS.

The adjuvant trials (HERA, APOLLO) demonstrated benefit when combined with chemotherapy
or as monotherapy for 1 year.

Pembrolizumab – For triple-negative early-stage breast cancer, adjuvant pembrolizumab in the KEYNOTE-522 trial improved event-free survival;
ongoing studies are clarifying its role.

C. Endocrine Therapy

Tamoxifen – Standard 5–10 years of tamoxifen for premenopausal patients
with ER+ disease, often combined with ovarian suppression (e.g., LHRH
agonists).

Aromatase Inhibitors – For postmenopausal women, typically
an AI (anastrozole, letrozole, exemestane) for 5–10 years.

Extended Therapy – Up to 10 years of tamoxifen or 8–10 years of AI may be
considered in high-risk patients.

D. Novel Agents

CDK4/6 Inhibitors (palbociclib, ribociclib, abemaciclib) with
endocrine therapy for advanced disease; evidence suggests benefit also in adjuvant setting (PALLAS trial).

PI3K Inhibitor Alpelisib for PIK3CA-mutated breast cancer.

4. Adjuvant Radiotherapy

Indication Typical Regimen

Tumor ≥5 cm, or 3 positive nodes, or any size
with nodal metastasis beyond level I Same as above; consider regional
nodal irradiation (supraclavicular, internal mammary) if ≥4
nodes positive

Notes:

The decision for boost and regional nodal RT should be individualized;
guidelines recommend considering patient comorbidities, tumour biology, and overall treatment time.

For patients undergoing mastectomy, the standard is
chest wall irradiation 50 Gy in 25 fractions with or without regional nodal RT based on nodal status.

3. Summary of Key Recommendations

Area Recommendation

Systemic therapy 1‑year endocrine therapy (tamoxifen/fulvestrant) for ER⁺/HER2⁻; consider extended
therapy if high risk.

Radiotherapy Post‑operative whole‑breast RT with or without
boost to tumour bed based on age, tumour size, margin status, and
lymph node involvement.

Timing Radiotherapy can be delivered before or after endocrine therapy; no definitive advantage of one
sequence over the other for this patient group.

These recommendations are drawn from current clinical guidelines (e.g.,
NCCN 2024, ESMO 2023) and recent evidence up to March 2025.
Adjustments may be needed based on evolving research
or patient-specific factors such as comorbidities, preferences, or emerging
molecular markers.

—

References:

deca dianabol test cycle

androgens definition

References:

steroids.com forum – https://Toolwala.com/product/bearing-puller/,

do steroids increase testosterone

References:

how to get bigger without steroids (https://git.deadpoo.net/Marlenecastle9)

where do anabolic steroids come from

References:

Mail Order Steriods (Gitea.Wholelove.Com.Tw)

what are the effects of steroids

References:

http://shenasname.ir/ask/user/versemelody96

legal steroids buy

References:

http://www.bidbarg.com

natural bodybuilding supplement stack

References:

maps.google.mw

liquid prohormones for sale

References:

forum.myjane.ru